ANGLE plc appoints James M. Reuben as Scientific Advisor

ANGLE plc (AIM:AGL OTCQX:ANPCY), a medical diagnostics company with pioneering products for cancer diagnostics and fetal health, is pleased to announce the appointment of James M. Reuben, PhD, MBA, as a Scientific Advisor to the company with immediate effect.

Dr. Reuben is a Professor in the Department of Hematopathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center, Houston, Texas. He has conducted significant research on circulating tumor cell subsets, including those with epithelial and mesenchymal phenotypes and their clinical relevance to minimal residual disease in breast cancer.

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centres devoted exclusively to cancer patient care, research, education and prevention. A different part of MD Anderson is already working with ANGLE as a key opinion leader in the field of colorectal cancer.

Related publications include "Circulating tumor cells, disease progression, and survival in metastatic breast cancer" in the New England Journal of Medicine; "Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients" in the British Journal of Cancer; and "Circulating tumor cells in metastatic inflammatory breast cancer" published in the Annals of Oncology.

Dr. Reuben received his PhD in immunology from McGill University in Montreal, Canada and his MBA from University of Houston, Houston, Texas. He completed his research fellowship in the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center with Evan M. Hersh, MD and Emil J Freireich, MD, as mentors.

For the past 30 years, Dr. Reuben has been a member of the American Association for Cancer Research (AACR), and the American Society of Clinical Oncology (ASCO). He has also been a member of the American Society of Hematology since January, 2000.

ANGLE is currently commercializing the Parsortix system, a cell separation technology that enables a simple blood test to capture targeted cells, such as circulating tumor cells (CTCs) for molecular profiling and analysis. Parsortix can help deliver targeted cancer diagnostics designed to inform personalized treatment of cancer. It is also designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug’s effectiveness.

ANGLE has established formal collaborations with world-class cancer centers and is working with these cancer centers to demonstrate key applications for its Parsortix non-invasive cancer diagnostic system as a liquid biopsy. In addition to cancer cells, the Parsortix technology has the potential for deployment for other clinically significant cell types in the future.

"Jim Reuben has exceptional knowledge of circulating tumor cells. He was one of the leading investigators in the earliest studies on CTCs and has been very actively involved ever since," said Andrew Newland, Founder and CEO of ANGLE. "We are delighted that he has joined ANGLE’s Scientific Advisory Board and believe his in-depth knowledge and understanding of CTCs and wide network of contacts in the field will be of great benefit to ANGLE as we drive towards the widespread adoption of the Parsortix system in cancer care."

About ANGLE plc

ANGLE is a UK-based specialist medtech company commercializing the Parsortix system, a cell separation technology that enables a simple blood test to capture targeted cells for investigation, such as circulating tumor cells (CTCs) for molecular profiling and analysis. Parsortix can help deliver targeted cancer diagnostics that has the potential to inform personalized treatment of cancer. It is also designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug’s effectiveness. ANGLE has established formal collaborations with world-class cancer centers and is working with these cancer centers to demonstrate key applications for its Parsortix non-invasive cancer diagnostic system as a liquid biopsy. In addition to cancer cells, the Parsortix technology has the potential for deployment for other clinically significant cell types in the future.

ANGLE is a public company trading on the AIM market of the London Stock Exchange under the ticker symbol AGL and on the OTCQX market in the US under the ticker symbol ANPCY. For more information, www.angleplc.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150603005268/en/